


NINETEENTH CONGRESS OF THE)
REPUBLIC OF THE PHILIPPINES)
First Regular Session)

'22 JUL -7 P4 :58

SENATE

RECEIVED BY:



S. No. 196

Introduced by Senator Christopher Lawrence "Bong" T. Go

**AN ACT
PROVIDING FOR THE FRAMEWORK FOR THE ESTABLISHMENT AND
OPERATION OF VIROLOGY LABORATORIES IN THE PHILIPPINES,
CREATING FOR THE PURPOSE THE VIROLOGY SCIENCE AND TECHNOLOGY
INSTITUTE OF THE PHILIPPINES (VIP), APPROPRIATING FUNDS
THEREFOR AND FOR OTHER PURPOSES**

EXPLANATORY NOTE

The recent COVID-19 pandemic exposed the world's unpreparedness in handling viral diseases, which led to numerous losses of jobs, economic growth opportunities, and most importantly, lives. In the Philippines, its impact's footprints are still visible, but similar events in the future are definitely preventable.

Outbreaks like COVID-19 could have been prevented or handled more efficiently in the presence of a national virology laboratory that will conduct surveillance, diagnosis and monitoring of viral diseases in humans, plants and animals. Issues like the recent pandemic and other non-human related viruses should be handled with urgency, enough funding, and with the best instruments.

As the government strive to address the situation and save more lives, we must learn from these experiences, identify gaps in government response mechanisms, and be more proactive in preparing for other similar crises in the future.

In the long term, investing heavily on health research initiatives should be

pursued. The virology institute will capacitate the country to conduct scientific research initiatives on preventing and treating various viruses and diseases.

This bill seeks to establish a reliable national virology laboratory that shall play a critical role in surveillance, diagnosis and monitoring of viral diseases in humans, plants and animals as well as in the understanding of the genetic changes in their viral genome as a prerequisite for a strong public health response to emerging, re-emerging and existing viral diseases in order to raise the level of health of the Filipino and improve their social, economic and cultural conditions.

In view of the foregoing, approval of this bill is earnestly sought.


SENATOR CHRISTOPHER LAWRENCE "BONG" T. GO 

NINETEENTH CONGRESS OF THE)
REPUBLIC OF THE PHILIPPINES)
First Regular Session)

*22 JUL -7 P4 :59

SENATE
S. No. 196

RECEIVED BY: 

Introduced by Senator Christopher Lawrence "Bong" T. Go

AN ACT
PROVIDING FOR THE FRAMEWORK FOR THE ESTABLISHMENT AND
OPERATION OF VIROLOGY LABORATORIES IN THE PHILIPPINES, CREATING
FOR THE PURPOSE THE VIROLOGY SCIENCE AND TECHNOLOGY INSTITUTE
OF THE PHILIPPINES (VIP), APPROPRIATING FUNDS THEREFOR AND FOR
OTHER PURPOSES

Be it enacted by the Senate and House of Representatives of the Philippines in Congress assembled:

CHAPTER I
GENERAL PROVISIONS

1 **Section 1. Short Title.** - This Act shall be known as the "Virology Science and
2 Technology Institute of the Philippines (VIP) Act of 2022."
3

4 **Sec. 2. Declaration of Policy.** - It is hereby declared the policy of the State to
5 protect and promote the right to health of every Filipino by ensuring that they are
6 proactively protected from diseases.
7

8 Towards this end, it is also hereby declared the policy of the State to establish a
9 reliable national virology laboratory that shall play a critical role in surveillance,
10 diagnosis and monitoring of viral diseases humans, plants and animals as well as in the
11 understanding of the genetic changes in their viral genome as a prerequisite for a strong
12 public health response to emerging, re-emerging and existing viral diseases in order to

1 raise the level of health of the Filipino and improve their social, economic and cultural
2 conditions.

3

4 It is hereby further declared the policy of the State that a systematic approach
5 to the improvement of our health system requires the establishment of an institution
6 equipped with the necessary capacity, competency, latitude and authority to decisively
7 and scientifically respond to the demands of public health and public health
8 emergencies, crises and situations brought about by viral infections and regulate the
9 operation of other virology laboratories in order to prevent possible public health threats
10 resulting from the operation of these laboratories.

11

12 **Sec. 3. Definition of terms.** - As used in this Act, the following terms shall mean:

13 (a) *Biosafety* is the application of safety precautions that reduce a laboratory
14 personnel's risk of exposure to a potentially infectious microbe and limit
15 contamination of the work environment and ultimately the community;

16 (b) *Biosafety levels* are divided into four (4). Each level has specific controls for the
17 containment of microbes and biological agents based on internationally-accepted
18 safety standards. The primary risk that determines the levels of containment are
19 infectivity, severity of disease transmissibility and the nature of the work conducted;

20 (c) *Culture medium or growth medium* is a liquid or gel designed to support the growth
21 of microorganisms;

22 (d) *Disinfection* is the process using chemical compounds to exterminate
23 microorganisms but does not necessarily kill all microorganisms especially resistant
24 bacterial spores;

25 (e) *Infectious waste* has been defined to include biological waste, cultures and stocks,
26 pathological waste, and sharps. Each of these categories has a proper disposal
27 method. Infectious wastes must either be incinerated or treated prior to disposal.

28 The following are the infectious wastes:

29 i. *Biological waste* includes blood and blood products, excretions, exudates,
30 secretions, suctionings and other body fluids that cannot be directly discarded
31 into the municipal sewer system, but excludes articles contaminated with fully
32 absorbed or dried blood. Biological waste must either be incinerated, sterilized

- 1 with steam in a dedicated autoclave as described below, or treated by some
2 other nationally recognized method which has been approved and formally
3 adopted by the Department of Environment and Natural Resources (DENR).
4 After treatment, biological waste may be treated as normal refuse.
- 5 ii. *Cultures and stocks* include etiologic agents and associated biologicals,
6 including specimen cultures and dishes and devices used to transfer, inoculate
7 and mix cultures. The definition also includes wastes from the production of
8 biologicals, serums, and discarded live or attenuated vaccines. Cultures and
9 stocks must be treated in the same way as biological waste.
- 10 iii. *Pathological waste* includes biopsy materials, all human tissues, and anatomical
11 parts from surgery and other procedures. It also includes carcasses and
12 bedding from animals and plants exposed to pathogens in research, but does
13 not include teeth or preservative agents such as formaldehyde. Pathological
14 waste must be incinerated.
- 15 iv. *Sharps* includes needles, scalpel blades, lancets, glass tubes that could be
16 broken during handling and syringes that have been removed from their original
17 sterile containers. Sharps must be incinerated.
- 18 (f) *Kit* or test kit is a commercially packaged system of the principal or key components
19 of an analytical method used to determine the presence of a specific analyte(s) in
20 a given matrix (es). Test kits include directions for their use and are often self-
21 contained, complete analytical systems; but they may require supporting supplies
22 and equipment. The key components frequently represent proprietary elements or
23 reagents that may be readily prepared only by the producer of the kit.
- 24 (g) *Personal protective equipment* consists of garments placed to protect a laboratory
25 scientist, worker or any other person from getting infected by a viral agent. It
26 consists of standard precautions: gloves, masks and gowns. When working with
27 blood or airborne high infections, it shall also include face protection, goggles and
28 masks or faces shields, gloves or coveralls, head cover and rubber boots;
- 29 (h) *Reagent* is any natural or synthetic substance used in a chemical or biological
30 reaction in order to produce, identify, or measure another substance;
- 31 (i) *Risk Group I viruses* are microorganism that is unlikely to cause human, plant or
32 animal disease (e.g. Adeno-associated vims (AAV) types 1-4). These viruses shall

- 1 be studied in basic virology laboratories;
- 2 (j) *Risk Group 2 viruses* (moderate individual risk, low community risk) are viral
3 pathogens that can cause human, plant or animal disease but are unlikely to be a
4 serious hazard to laboratory workers, the community, livestock or the environment.
5 Laboratory exposures to these group of viruses may cause serious infection, but
6 effective treatment and preventive measures are available and the risk of spread of
7 infection is limited. Assay systems using these viruses shall be done in biosafety
8 level 2 laboratories. Examples include herpes viruses, foot-and- mouth disease
9 viruses, adenoviruses and unconventional slow viruses;
- 10 (k) *Risk Group 3 viruses* (high individual risk, low community risk) are viral pathogens
11 that usually cause serious human, plant or animal disease but does not ordinarily
12 spread from one infected individual to another. Effective treatment and preventive
13 measures are available against these group of viruses. Assay systems using these
14 viruses shall be conducted in biosafety level 3 laboratories. Examples include human
15 immunodeficiency vims (HIV), hepatitis B vims (HBV), hantaviruses, Japanese
16 encephalitis vims (JEV), rabies, rift valley fever and yellow fever vims;
- 17 (l) *Risk Group 4 viruses* (high individual and community risk) are viral pathogens that
18 usually cause serious human, plant or animal disease and that can be readily
19 transmitted from one individual to another, directly or indirectly. Effective treatment
20 and preventive measures are not usually available against these group of viruses.
21 Assay systems using these viruses shall be made in biosafety level 4 laboratories.
22 Examples include Lassa fever, filoviruses, smallpox, Crimean- Congo haemorrhagic
23 fever, avian influenza viruses, Nipah virus, Russian spring-summer encephalitis and
24 Kyasanur forest disease viruses;
- 25 (m) *Serology* is the scientific study or diagnostic examination of blood serum, especially
26 with regard to the response of the immune system to pathogens or introduced
27 substances;
- 28 (n) *Smear* is a specimen for microscopic study, the material being spread thinly and
29 unevenly across the slide with a swab or loop, or with the edge of another slide;
- 30 (o) *Sterilization* is the process of exterminating all microorganisms within or outside an
31 object or material using extreme chemical or physical;
- 32 (p) *Tissue culture* refers to a collection of laboratory techniques and methods in which

1 fragments of a tissue (human, plant or animal tissue) are introduced into a new,
2 artificial environment, where they continue to function or grow; and
3 (q) *Virology* is the study of viruses, vims-like agents including but not limited to their
4 taxonomy, disease-producing properties, cultivation and genetics.

5
6 **CHAPTER II**
7 **VIROLOGY SCIENCE AND TECHNOLOGY**
8 **INSTITUTE OF THE PHILIPPINES**
9

10 ***Sec. 4. Creation of a Virology Science and Technology Institute of the***
11 ***Philippines (VIP).*** - There is hereby created a Virology Science and Technology
12 Institute of the Philippines (VIP), hereinafter referred to as the Institute.

13
14 The Institute shall be as an attached agency under the Department of Science
15 and Technology (DOST). The DOST, in coordination with the Department of Agriculture
16 (DA) and the Department of Health (DOH), shall promulgate policies for and exercise
17 supervision and control over the Institute.

18
19 ***Sec. 5. Scope and Coverage of Virology Science and Technology.*** - For
20 purposes of this Act, the scope and coverage of the Institute shall be the extensive,
21 ground-breaking, pioneering and original research projects on the study of viruses for
22 agricultural, industrial, clinical and environmental importance, contagious and non-
23 contagious viral diseases from the standpoint of preventive medicine in humans,
24 animals and plants, improving human, zoological and botanical health and welfare by
25 suppressing infectious and non-infectious viral diseases, and clarifying and supporting
26 the scientific background of viruses in relation to zoological, botanical and human health
27 and medical administration of the government: *Provided,* That the Institute shall be the
28 national reference laboratory for all zoonotic and botanical infections involving viral
29 etiology.

30
31 ***Sec. 6. The Director of the Institute.*** - The Institute shall be headed by a
32 Director, who shall have a rank of an undersecretary and shall be appointed by the

1 President of the Philippines upon the recommendation of the Advisory Board created
2 under Section 9 of this Act. The Director shall be a qualified virologist possessing a
3 postgraduate degree in virology with three (3) to five (5) years of experience in
4 diagnostic virology.

5
6 The Director shall have overall responsibility for the activities including the
7 supervision of all the staff working in the Institute, and shall be directly responsible for
8 reporting to the Secretary of Science and Technology and the President of the
9 Philippines the results of the various diagnostic assays and research studies performed
10 in the Institute.

11
12 The Director shall be responsible for the implementation of policies and the
13 immediate management of the programs and operations of the Institute including its
14 general institutional affairs, promote research and foster efficient assay and research
15 activities.

16
17 The Director shall be assisted by a Deputy Director, who shall have a rank of an
18 assistant secretary, and shall be appointed by the President of the Philippines upon the
19 recommendation of the Advisory Bouncil.

20
21 **Sec. 7. Powers and Functions.** - The Institute shall be the principal laboratory of
22 the country in providing quality virology laboratory investigations, researches and
23 technical coordination of the entire network of the virology laboratories in the
24 Philippines.

25
26 The Institute shall perform the following functions:

- 27 (a) Conduct basic and applied research projects on zoological, botanical and human
28 infectious, non-infectious and other intractable diseases of viral etiology with
29 primary focus on their characterization, vector/reservoir transmission, viral ecology,
30 clinical virology, pathogenesis, pathophysiology, and host immune response to
31 these viral pathogens;
- 32 (b) Provide reference services including all that are necessary for ensuring the assay

- 1 systems for diseases of viral etiology, industrial and technological implications of
2 virology and services involving the storing and supplying pathogenic and non-
3 pathogenic viral agents and their vectors and hosts, standardizing reagents,
4 preparing and supplying reference materials needed for the diagnosis and
5 surveillance of plant, animal and human diseases, educating professional
6 technicians, and information exchange;
- 7 (c) Establish testing, reference and biosafety levels 1,2 3, and 4 research laboratories
8 which are fully compliant with the provisions of this Act and the internationally-
9 accepted guidelines in the establishment and operation of the same;
- 10 (d) Conduct viral disease surveillance program, collection, analysis, and feedback and
11 distribution of information on diseases of viral etiology;
- 12 (e) Comprehensively coordinate the planning and implementation of research projects,
13 approve liaison and coordination with relevant governmental agencies, and
14 coordinate research projects with other research institutions;
- 15 (f) Provide technical advice to national authorities on the progress, needs and
16 aspirations of the virology laboratory network in the country and to regulate the
17 operation of the same;
- 18 (g) Assist national authorities in the planning, organization and supervision of the
19 virology laboratory network;
- 20 (h) Develop technical/training material for use in laboratories in the network to enhance
21 their quality;
- 22 (i) Assess the needs and impart training to the staff of other virology laboratories in
23 the country in quality testing for viral pathogens;
- 24 (j) Validate reagents and kits that may be used nationally;
- 25 (k) Validate new technologies that may become available and recommend their
26 implementation in the country;
- 27 (l) Develop minimum standards, standard operating procedures and research
28 protocols for virology laboratories and assist virology laboratories in their
29 implementation of the same;
- 30 (m) Develop, in consultation with the DOH, DA, other relevant government agencies,
31 the academe, and private enterprises engaged in the industry of virology, a national
32 database of viruses and laboratory results;

- 1 (n) Organize external quality assessment schemes to periodically assess the quality of
2 testing in networks and suggest remedial measures to those laboratories that show
3 poor performance;
- 4 (o) Undertake research to improve the quality and cost-effectiveness of virology
5 laboratory services in the country;
- 6 (p) Collaborate with the World Health Organization (WHO) and other international
7 agencies in virology researches and technical matters pertaining to improvement of
8 laboratories;
- 9 (q) Create within the Institute various divisions that will spearhead basic and applied
10 molecular biological research and reference activities in arbovirology, emerging and
11 reemerging viral diseases, neurovirology, herpes virology, enteric virology, tumor
12 virology, hepatitis virology, acute viral respiratory infections and cytokines, viral
13 genomics and molecular genetics and biosafety control studies of viruses, among
14 others;
- 15 (r) Promulgate rules and regulations regarding the management and operation of
16 virology laboratories in the country as well as its rules of engagement;
- 17 (s) Collect fees in connection with the exercise of its regulatory powers;
- 18 (t) Apply for, receive, and accept bequests, grants, and donation of funds, equipment,
19 materials and services needed for the attainment of its objectives;
- 20 (u) Provide grants, research fund, materials and equipment for the conduct of virology
21 researches by both public and private higher education institutions;
- 22 (v) Order the suspension or closure of virology laboratories and prosecution of
23 individuals and corporations for violations of this Act;
- 24 (w) Establish an editorial office of a refereed journal of virology to published it and a
25 library which shall to collect and preserve books, journals and other reference
26 materials in the field of virology; and
- 27 (x) Perform such other related activities as may be assigned by the DOST.

28

29 **Sec. 8. *Organization and Personnel.*** - The Institute shall have its technical
30 and administrative support staff as well as consultants as may be necessary. Such
31 consultants may be drawn from the public and private sectors on consultancy or
32 contractual basis and shall be granted honoraria or allowances at such amounts as may

1 be determined in accordance with existing rules and regulations.

2
3 All laboratory workers shall undergo periodic training to increase their laboratory
4 competencies. Attendance to conferences, seminars and trainings shall be given
5 additional service credits.

6
7 **Sec. 9. *Advisory Board.*** - The Institute shall have an Advisory Board composed
8 of the following officials or their representatives:

9 (a) The Secretary of Science and Technology, Chairman;

10 (b) The Secretary of Health, Co-Chairman;

11 (c) The Secretary of Agriculture, Co-Chairman; and

12 (d) Ten (10) members from the academe who must have distinguished
13 themselves in the field of medical virology, genomics, plant virology, animal
14 virology, epidemiology, genetic engineering and other related disciplines and
15 shall be appointed by the President of the Philippines.

16
17 **Sec. 10. *Transfer of Biomedical Research Functions.*** - All functions in the
18 Department of Health involving biomedical research in virology and in the Department
19 of Agriculture involving animal and plant virology shall be transferred to the Institute
20 together with their applicable appropriations, records, equipment, property and such
21 personnel as may be necessary.

22
23 Notwithstanding the provisions of this law, the Research Institute for Tropical
24 Medicine shall retain its existing mandate on reference laboratories for public health
25 purposes, as stipulated in relevant laws and rules.

26 27 **CHAPTER III**

28 **VIROLOGY LABORATORY OPERATIONS**

29
30 **Sec. 11. *Physical structure of virology laboratories.*** - All newly constructed
31 virology laboratories shall be located in separate, multi-storied buildings.

1 A virology laboratory shall be situated at the end of a corridor in a building where
2 other laboratories are located in order to restrict entry of visitors, prevent contamination
3 and facilitate maintaining biosafety standards. In cases of existing laboratories, they
4 shall be separated from other areas and facilities that are open to unrestricted staff
5 movement within the building.

6
7 **Sec. 12. Essential features of a virology laboratory.** - Apart from the
8 biosafety requirements, the following shall be the minimum essential features that must
9 to be incorporated in the design of a virology laboratory:

10 (a) Adequate space shall be provided for the safe conduct of laboratory work and for
11 cleaning and maintenance. Designated cubicles, rooms or areas shall be available
12 to carry out different activities, e.g. office rooms, specimen collection cubicle,
13 specimen reception and processing room, serology laboratory, cell culture cubicle,
14 molecular diagnostic laboratory comprising three cubicles, cold room, dark room
15 for fluorescent microscopy, common equipment room, media preparation room,
16 washing and sterilization section, store room, toilets and lunch room;

17 (b) Each laboratory room shall have a space for housing a biosafety level 2 cabinet,
18 one workbench, a sink, discard bins, wall cabinets to store consumables, a
19 centrifuge, an incubator and a refrigerator;

20 (c) The entire laboratory shall be climate-controlled to maintain a dust-free
21 environment and an ambient temperature of 22-25 °C. Least cell culture cubicles,
22 virus handling cubicles, the serology lab and the molecular biology labs shall also
23 be air conditioned;

24 (d) Walls, ceilings and floors shall be smooth, easy to clean, impermeable to liquids
25 and resistant to chemicals and disinfectants normally used in the laboratory. Floors
26 shall be slip- resistant;

27 (e) Bench-tops shall be impervious to water and resistant to disinfectants, acids,
28 alkalis, organic solvents and moderate heat;

29 (f) Illumination shall be adequate for all activities. Undesirable reflections and glare
30 shall be avoided;

31 (g) Laboratory furniture shall be sturdy. Open spaces between and under benches,
32 cabinets and equipment shall be accessible to cleaning;

- 1 (h) Storage space shall be adequate to hold supplies for immediate use and thus
2 prevent clutter on bench tops and in aisles. Additional long-term storage space
3 conveniently located within or outside the laboratory area shall also be provided;
- 4 (i) All doors shall have vision panels, appropriate fire ratings and self-closing;
- 5 (j) Facilities for storing outer garments, personal items, pantry and restrooms shall
6 be provided outside the laboratory working area;
- 7 (k) Hand-washing basins with running tap water shall be provided in each laboratory
8 room, preferably near the exit door. A dependable supply of good quality water
9 shall essential. There must be no cross-connections between sources of laboratory
10 water supply and drinking water supplies;
- 11 (l) There shall be reliable and adequate electricity supply and emergency lighting for
12 safe exits. A stand-by generator shall be available at least for some equipment
13 such as incubators, biosafety cabinets, freezers etc.; and
- 14 (m) Safety systems shall cover fire, electrical emergencies, emergency shower and
15 eyewash facilities including systems for avoiding overcrowding and too much
16 equipment, pest control and prevention particularly rodents and arthropods and
17 prevention of unauthorized entry into the laboratory areas.

18

19 **Sec. 13. *Equipment and supplies.*** - The virology laboratory shall have adequate
20 equipment which shall take into account certain general principles, including:

- 21 (a) The equipment, facilities and supplies must be designed to prevent or limit contact
22 between the operator and the infectious material (e.g. biosafety cabinets, electronic
23 pipetting aids, etc.);
- 24 (b) The equipment and facilities must be made of materials that are impermeable to
25 liquids, resistant to corrosion and meet internationally-accepted structural
26 requirements;
- 27 (c) The equipment and facilities must be free of sharp edges, burrs and unguarded
28 moving parts;
- 29 (d) The equipment and facilities must be designed, constructed and installed to facilitate
30 simple operation and provide for ease of maintenance, cleaning, decontamination
31 and certification testing; and
- 32 (e) Glasswares and other breakable materials must be avoided wherever possible.

1 Essential and desirable equipment required for a virology laboratory must conform
2 with standards set by the Institute and internationally-recognized manuals and
3 guidelines for virology laboratory operations.
4

5 **Sec. 14. Biosafety requirements of laboratories.** - The biosafety infrastructure
6 shall be designed on the basis of risk assessment for handling specific pathogens. The
7 desired biosafety levels shall be established on the basis of professional judgement
8 based on risk assessment and on internationally-accepted guidelines on the handling
9 and management of specific viral agents.

10 (a) In addition to the minimum essential features stipulated in Section 12, a biosafety
11 level 2 laboratory shall have the following minimum requirements:

- 12 1. Inward airflow ventilation or controlled ventilating system;
- 13 2. On-site Autoclave: and
- 14 3. Biological safety cabinets.

15 (b) In addition to the minimum essential features stipulated in Section 12, biosafety
16 level 3 and 4 laboratories shall have the following minimum requirements:

- 17 1. Isolation of laboratory;
- 18 2. Room sealable for decontamination;
- 19 3. Inward airflow ventilation, controlled ventilating system and HEPA-filtered;
- 20 4. Double-door entry;
- 21 5. Airlock;
- 22 6. Airlock with shower;
- 23 7. Anteroom;
- 24 8. Anteroom with shower;
- 25 9. Effluent treatment;
- 26 10. On site, in-laboratory and double-ended Autoclave;
- 27 11. Biological safety cabinets; and
- 28 12. Personal safety monitoring capability.

29 (c) Biosafety level 3 and 4 laboratories must be separated from general traffic flow and
30 accessed through an anteroom (with double door entry or basic laboratory - Biosafety
31 Level 2) or an airlock.

32 (d) An autoclave must available within the facility for decontamination of wastes prior to
33 disposal.

1 (e) A sink with hands-free operation must available.

2 (f) Inward directional airflow must be established and all work with infectious materials
3 must conducted within a biological safety cabinet.

4
5 *Sec. 15. Handling of viruses and specimens containing viruses.* - Unless the
6 recommended biosafety level facilities are available, the laboratory should not handle a
7 particular virus. In situations where there is an outbreak of a viral illness and the required
8 biosafety levels are not available, the specimen shall be collected and referred to the
9 nearest laboratory that has the required biosafety laboratory. Specimens collected from
10 patients who are suspected of suffering from viral infections caused by agents under
11 risk groups 3 or 4 shall be directly forwarded to the reference laboratory or the Institute
12 which has the required facilities for the handling such agents.

13
14 *Sec. 16. Minimum staff requirement for a virology laboratory.* - The minimum
15 staff requirements for a virology laboratory shall include:

16 (a) A qualified virologist possessing a postgraduate qualification in virology
17 with three years of experience in diagnostic virology shall be the chief of the laboratory.
18 He shall have overall responsibility for the activities of the laboratory and shall supervise
19 all the staff working in it. In addition, he shall be directly responsible for reporting results
20 of the various diagnostic assays performed in the laboratory;

21 (b) Two junior microbiologists possessing a master's degree in medical, animal
22 or plant microbiology with one to two years of experience in diagnostic virology. These
23 microbiologists shall be responsible for the day-to-day operation of the laboratory
24 including the supervision of technical staff who carry out the various diagnostic tests,
25 stock management and procurement of laboratory supplies and diagnostic kits, quality
26 control and quality assurance;

27 (c) Two laboratory technologists possessing a bachelor's degree in medical
28 technology, one to be trained in cell culture and virus isolation methods and the other
29 to be trained in serology. The technicians shall be responsible for specimen processing,
30 testing, laboratory safety, maintenance of laboratory records and media preparation;
31 and

32 (d) One or two laboratory supportive staff.

33 (e) The duties and responsibilities of all the staff shall be clearly outlined and

1 they shall be provided with periodic training to upgrade the knowledge and skills
2 of the laboratory operation and management to ensure that the laboratory is
3 abreast with contemporary diagnostic methodology as well as maintain quality in
4 the services rendered.

5
6 **Sec. 17. Use of personal protective equipment in virology laboratories.**

7 - Specially designed coveralls which afford protection up to the neck, facemasks or frill
8 face respirators and gloves shall be used at all times in the virology laboratory. Additional
9 personal protective equipment shall be used when handling highly pathogenic viruses.

10
11 **Sec. 18. Amenities.** - Hand basins must be provided in each laboratory. Lockers
12 for staff clothing must be available outside but near the laboratory rooms. Pantry/rooms
13 for eating and drinking must be provided close to laboratory rooms.

14
15 **Sec. 19. Health of staff.** - Pre-employment medical examination for all staff shall
16 be made. Medical monitoring for workers in biosafety level 3 and 4 laboratories shall
17 also be conducted regularly. The scope of the monitoring shall depend on the agent
18 being handled. Women who work with viruses must disclose their pregnancy as soon as
19 possible. Individual evaluation of the risks involved in continued employment in the
20 virology laboratory must also be done.

21
22 **Sec. 20. Medical surveillance.** - A system that records and follows up all cases of
23 illness among laboratory staff to ascertain the source of infection and initiate any follow-
24 up action shall be developed.

25
26 **Sec. 21. Accidents.** -

27 (a) All accidents causing personal injury with or without exposure to infectious agents
28 shall be reported to the supervisor or safety officer. Records should be kept of all
29 staff sicknesses, injuries and accidents, and of x-rays and immunization;

30 (b) A qualified first-aid provider must be present at all times in the laboratory. He/she
31 must receive additional training in dealing with exposure to and ingestion of
32 infectious, toxic and corrosive chemicals;

33 (c) A well sign-posted standard first aid kit for minor injuries must be in a conspicuous

1 location inside the laboratory; and

- 2 (d) Standard operating procedures for management of post-exposure prophylaxis
3 must be in place.

4
5 **CHAPTER IV**

6 **LABORATORY WASTE MANAGEMENT**

7
8 *Sec. 22. Management of laboratory waste.* - Laboratory waste shall be segregated
9 into color-coded containers corresponding those for incineration, for autoclaving, normal
10 household waste and for soiled linens.

11
12 The following practical methods shall be used in treating contaminated laboratory
13 waste:

- 14 (a) Sterilization by autoclaving using timed exposure of materials to steam above
15 atmospheric pressure at temperatures above 100°C.
- 16 (b) Chemical disinfection which is regarded as the first line defense, especially in the
17 case of discarded bench equipment, and which should be followed by autoclaving
18 or incineration. Chemical disinfection shall use clear sodium hypochlorite, clear
19 phenolics, alcohols and aldehydes.
- 20 (c) Incineration involves the transport of waste materials off-site for disposal using an
21 incinerator.
- 22 (d) Other internationally-accepted forms of disinfection and decontamination shall be
23 employed in effectively preventing accidents and contamination.

24
25 *Sec. 23. Infectious waste.* - Infectious wastes shall be segregated from general
26 wastes as they need to be autoclaved or incinerated before being removed from the
27 area in which they are generated.

28
29 *Sec. 24. Routine contaminated wastes.* - Laboratory workers shall take care to
30 segregate their wastes from general wastes. General wastes shall be decontaminated
31 prior to removal from the area in which they are generated. Internationally-accepted
32 alternative means of decontamination to autoclaving or incineration may be used,
33 provided they are effective.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Sec. 25. *Management of sharps.* - All sharps shall be segregated from other wastes and placed in dedicated and labelled single-use rigid containers immediately after use. Sharps containers shall not be compacted or emptied into ordinary waste streams.

Sec. 26. *Labelling of wastes.* -

- (a) All wastes shall be identified with an appropriate type of label which shall remain attached to the waste. The label shall state the nature of waste material, the department, date, and the name of the person responsible for the waste.
- (b) In transporting wastes through buildings and across campus, the main consideration shall be the non-exposure of anyone to the risks from the contaminated material. Containers shall be leak-proof.
- (c) Wastes shall be decontaminated as far as is practical before removal from the area of generation. All laboratories shall have access to local autoclave and other appropriate decontamination facilities so as to minimize the need to transport contaminated wastes around laboratories.

CHAPTER V
QUALITY SYSTEMS IN VIROLOGY LABORATORIES

Sec. 27. *Quality systems.* - A quality system shall be instituted in all virology laboratories. It shall be comprehensive and shall cover all aspects from the decision to collect the specimen to the interpretation of results. Systematic efforts through organizational structure and efficient utilization of resources shall be used implement all the steps that shall assure generation of quality reports by the laboratory. It shall aim at consistency, reproducibility, traceability and efficaciousness of the laboratory services.

Sec. 28. *Documentation.* - Routine procedures shall be described in written Standard Operating Procedures (SOPs). They shall be reviewed regularly and modified, if necessary. The modified versions shall be signed and dated by the laboratory director. The most recent version of SOPs shall be available directly at the work place. The old versions shall be kept in the laboratory and shall be archived if required. The records shall be stored for long periods of time but shall be available for prompt retrieval. Safe

1 archiving of all records shall be ensured.

2

3 Archiving of the source documents and other essential documents shall be done in such
4 a way that data are kept in an integer state and can neither be lost nor altered to achieve
5 this goal. Records of usage, maintenance and calibration shall be kept in the laboratory
6 and shall be routinely monitored. Reports of the tests shall be released only after proper
7 scrutiny and documentation of the scrutiny with the signature and date by the laboratory
8 supervisor.

9

10 **Sec. 29. *Standard operating procedure (SOP).*** - SOP is one of the most
11 important documents in a diagnostic laboratory. Apart from providing the complete
12 details of how exactly a test or a procedure is carried out in a laboratory, the SOP shall
13 provide information on specimen collection, laboratory safety instructions, purpose and
14 limitations of the procedure, turnaround times, interpretation of results, and above all,
15 the line of authority. The procedure manual used in the laboratory shall be complete
16 enough in detail in order that any laboratory scientist can perform the procedure without
17 additional information. One copy of the manual shall be readily available to bench
18 personnel, and another copy shall be stored separately in case of accidents. A document
19 control system shall be instituted to ensure that up-to-date document are used.

20

21 **Sec. 30. *Quality control checks areas.*** - The following, among others, shall
22 be the minimum critical quality control check areas:

23 (a) *Specimen transport.* Viral specimens held for short periods shall be
24 refrigerated, while those for longer periods shall be frozen at -20°C or -70°C;

25 (b) *Transport media.* The composition and type of viral transport media can affect
26 viral isolation rates. Culture media shall be a balanced isotonic solution at
27 physiological pH. It shall contain a substance that will stabilize the virus such
28 as gelatin, fetal calf serum or bovine serum albumin, and antibiotics against
29 bacteria and fungi. The swab shall be made of a material that is non-toxic to
30 viruses

1 (c) *Smears*. Smears must contain a reasonable number of cells, be of a reasonable
2 size, and not mixed with blood or pus in order to avoid non-specific staining;

3 (d) *Specimens for serology*. Excessively haemolyzed, lipaemic, bacterially-
4 contaminated, or leaking specimens shall be rejected. Sera shall be heat-
5 inactivated depending on the tests to be performed. In the event of a specimen
6 being rejected, the sender shall be informed, preferably by an oral report
7 followed by a written one. Extenuating circumstances may warrant the
8 acceptance of a substandard specimen;

9 (e) *Tissue culture and media*. Within a given cell line, there may be significant
10 variations in sensitivity to vims isolation which may depend on the particular cell
11 line or clone and the passage number. Information on a particular cell line shall
12 be recorded accurately including the source, type, passage number, confluency
13 and cell condition. These back-up systems shall include freezing and storage of
14 low passage cells at -70°C liquid nitrogen tanks, use of paired stock flasks or
15 carrying of a parallel set of stock flasks using a separate set of tissue culture
16 reagents and glassware;

17 Other quality control procedures that may aid in minimizing the risk of
18 contamination shall include the exclusion of laboratory with infectious diseases
19 from handling tissue culture, and separate laboratory apparel, reagents and
20 glassware for tissue culture. Cell lines shall be handled separately and the
21 cabinet shall be decontaminated in between uses;

22 (f) *Media*. Following filter sterilization, aliquots of the media shall be taken and
23 checked for bacteriological or fungal contamination. These samples shall be
24 examined daily for five days and must be free from contamination. Aliquots of
25 all other medium components such as fetal calf serum and L-glutamine shall
26 also be checked. New lots of medium and fetal calf serum that have passed the
27 sterility check shall be monitored for their ability to support cell growth;

28 (g) *Reagents and kits*. Reagents and kits shall only be ordered from reputable
29 manufacturers and dealers with reliable transportation systems. Upon receipt,
30 the reagents shall be checked for obvious breakage or contamination. The
31 quantity, source, lot number and date of receipt shall be entered in a logbook
32 and the reagents stored according to the manufacturer's storage specifications.

1 When new lots of any reagent are opened, the date shall be noted on the
2 container. Caution shall be exercised in the case of kits as different components
3 of a kit may require different storage conditions and have different expiration
4 dates; and

5 (h) *Instruments.* Laboratory instruments shall be subjected to routine preventive
6 maintenance and checked and calibrated on a regular basis. Some of these
7 checks may be performed by laboratory staff and entered into a logbook. The
8 following shall be the minimum routine laboratory maintenance and
9 performance checks on instruments:

10 i. *Incubators:* daily temperature, CO₂ and humidity checks. Weekly
11 decontamination of interior;

12 ii. *Safety cabinets:* daily air pressure check and cleaning of UV lamp.
13 Work surface should be decontaminated after each use. Annual
14 checks for air velocity and filter integrity and paraldehyde
15 decontamination, as applicable;

16 iii. *Microscopes:* daily cleaning of objectives and stage, log of lamp
17 usage and annual overhaul. Refrigerators and freezers: daily
18 temperature check; annual check of compressor and refrigerant
19 levels;

20 iv. *Water baths:* daily temperature checks, weekly decontamination;

21 v. *Refrigerated centrifuges:* weekly decontamination, annual
22 inspection of motor, speed calibration and drive system;

23 vi. *Autoclaves:* daily temperature check and monthly spore strip
24 testing;

25 vii. *pH meters:* single reference buffer check before each use, multiple
26 point check monthly; and

27 viii. *Pipetting devices:* gravimetric volume check monthly; annual overhaul.
28

29 **Sec. 31. Continuing professional education.** - All virology laboratories shall
30 regularly provide local and international education and training to its laboratory
31 workers at the expense of the laboratory.
32

1 faults or omissions shall be punishable by imprisonment of at least 6 years and 1
2 day to 12 years (*prision mayor*) or a fine of not less than one hundred thousand
3 pesos (P100,000.00) but not more than one million pesos (P1,000,000.00), or both,
4 such imprisonment and fine, at the discretion of the court:

5 i. Any person who operates a virology laboratory in violation of Sections 11,
6 12, 13 and 14 of this Act.

7 ii. Any person who disposes laboratory waste in violation of Sections 22, 23,
8 24, 25 and 26 of this Act;

9 (c) In addition to acts or omissions already penalized by existing laws, the following
10 faults or omissions shall be punishable by imprisonment of at least 6 months and
11 1 day to 6 years (*prision correctional*) or a fine of not less than one hundred
12 thousand pesos (PI 00,000.00) but not more than five hundred thousand pesos
13 (P500,000.00), or both, such imprisonment and fine, at the discretion of the court:

14 i. Any person who operates a virology laboratory in violation of Sections
15 16, 17, 18, 19, 20 and 21 of this Act.

16 ii. Any person who operates a virology laboratory in violation of Sections
17 27, 28, 29, 30, 31, 32 and 33 of this Act;

18
19 **Sec. 35. Joint Penalty.** - Where a representative of a corporation, or an agent
20 or an employee of, or any other person employed by, a corporation or individual
21 commits any violation of the provisions of this Act in connection with the business of
22 the corporation or individual, in addition to the punishment of such violator, the
23 corporation or individual shall be punished by a fine under the respective provisions of
24 Section 34.

25
26 **Sec. 36. Administrative Penalty.** - In addition to acts or omissions already
27 penalized by existing laws, the any government official or employee who, by fault or
28 omission, violates any provision of this Act shall be perpetually disqualified from
29 holding public office with forfeiture of benefits in favor of the State.
30

1
2
3
4
5
6
7
8
9
10
11
12
13
14

CHAPTER VII
OTHER PROVISIONS

15
16
17
18
19
20
21
22
23
24
25

Sec. 37. Congressional Overnight Committee on the Virology Science and Technology Institute of the Philippines.— To monitor the implementation of this Act, there shall be a Congressional Oversight Committee on the Virology Science and Technology Institute of the Philippines, composed of the Chair and four (4) members of the House Committee on Science and Technology, Chair of the House Committees on Health and Agriculture and Food and the Chair and four (4) members of the Senate Committee on Science and Technology, and the Chair of the Committees on Health and Demography and Agriculture, Food and Agrarian Reform. No part of this Act shall be construed as to limit the oversight powers inherently or actually possessed by the same committees.

26
27
28
29
30
31
32

Sec. 38. Staffing. —The Secretary of Science and Technology, in consultation with the Department of Budget and Management (DBM), shall determine the organizational structures, qualification standards, staffing pattern and compensation of the newly created Institute and other positions which are established under this Act in accordance with existing laws, rules and regulations.

Sec. 39. Appropriations. - The amount needed for the initial implementation of this Act shall be taken from the current year's appropriations of the DOST. Thereafter, such sums, as may be necessary for its continued implementation, shall be included in the annual General Appropriations Act.

Sec. 40. Implementing Rules and Regulations. - The Secretary of Science and Technology shall promulgate the necessary rules and regulations within ninety (90) working days from the effectivity of this Act.

Sec. 41. Separability Clause. — If any portion or provision of this Act is subsequently declared invalid or unconstitutional, other provisions hereof which are not affected thereby shall remain in full force and effect.

1

2 **Sec. 42. *Repealing Clause.*** — All other laws, acts, presidential decrees,
3 executive orders, presidential proclamations, issuances, rules and regulations, or parts
4 thereof which are contrary to or inconsistent with any of the provisions of this Act are
5 hereby repealed, amended, or modified accordingly.

6

7 **Sec. 43. *Effectivity.*** — This Act shall take effect fifteen (15) days after its
8 publication in the Official Gazette or in a newspaper of general circulation.

Approved,